[Muscle-Specific Receptor Tyrosine Kinase Antibody Positive Myasthenia Gravis].
Brain Nerve
; 76(5): 623-629, 2024 May.
Article
em Ja
| MEDLINE
| ID: mdl-38741505
ABSTRACT
Reportedly, patients with muscle-specific kinase (MuSK) antibody-positive myasthenia gravis (MG) account for approximately 3.0% of all patients with MG in Japan. Compared with patients who have acetylcholine receptor antibody-positive MG, those with MuSK antibody-positive MG show young-onset disease with female predominance, a low rate of ocular involvement (5.9%), and greater severity of dysphagia. The aforementioned types of MG are indistinguishable based on clinical symptoms and electrophysiological tests, and measurement of MuSK antibodies is essential for diagnosis. Thymectomy and complement inhibitors are not indicated for treatment, and acetylcholinesterase inhibitors, steroids, immunosuppressants, plasma exchange, intravenous immunoglobulin therapy, and neonatal Fc receptor inhibitors are used.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Autoanticorpos
/
Receptores Colinérgicos
/
Receptores Proteína Tirosina Quinases
/
Miastenia Gravis
Limite:
Humans
Idioma:
Ja
Revista:
Brain Nerve
Ano de publicação:
2024
Tipo de documento:
Article